Abstract:Significance The design of cell-penetrating long peptidomimetic scaffolds for interacting with large protein binding interfaces is challenging because they involve various necessary functional groups. Here we report the first series of helical sulfono-γ-AApeptides that disrupt protein–protein interactions. Specifically, we discovered that these helical mimetics can structurally and functionally mimic the B Cell Lymphoma 9 (BCL9) helix and disrupt cancer-related β-catenin/BCL9 protein–protein interaction in cells with excellent potency and specificity. Enzymatic stability studies demonstrate the remarkable stability of the helical sulfono-γ-AApeptides, augmenting their biological potential. This strategy could be adapted to target a myriad of other disease-related protein–protein interactions. The rational design of α-helix–mimicking peptidomimetics provides a streamlined approach to discover potent inhibitors for protein−protein interactions (PPIs). However, designing cell-penetrating long peptidomimetic scaffolds equipped with various functional groups necessary for interacting with large protein-binding interfaces remains challenging. This is particularly true for targeting β-catenin/BCL9 PPIs. Here we designed a series of unprecedented helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B Cell Lymphoma 9 (BCL9). Our studies show that sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9 and selectively disrupt β-catenin/BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin/BCL9 PPIs, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, our enzymatic stability studies demonstrate the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential. This work represents not only an example of helical sulfono-γ-AApeptides that mimic α-helix and disrupt protein–protein interactions, but also an excellent example of potent, selective, and cell-permeable unnatural foldameric peptidomimetics that disrupt the β-catenin/BCL9 PPI. The design of helical sulfono-γ-AApeptides may lead to a new strategy to modulate a myriad of protein–protein interactions.

De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.

Rational Design and Cyclization of MIG6 Peptide to Restore Its Binding Affinity for ErbB Family Receptor Tyrosine Kinases

Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.

Structural Basis of Inhibition of ERα-Coactivator Interaction by High-Affinity N-Terminus Isoaspartic Acid Tethered Helical Peptides.

Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics

Design and Synthesis of Peptide-Drug Conjugates to Double Target EGFR

Targeted Covalent Inhibition of Grb2-Sos1 Interaction Through Proximity-Induced Conjugation in Breast Cancer Cells.

<i>In</i><i> Silico</i> Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer

Synthesis and Utilization of Chiral α-Methylated α-Amino Acids with a Carboxyalkyl Side Chain in the Design of Novel Grb2-SH2 Peptide Inhibitors Free of Phosphotyrosine

In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer

In Silico Design of MDM2-Targeting Peptides from Naturally Occurring Constrained Peptide.

Structure-Based Design of Peptides against G3BP with Cytotoxicity on Tumor Cells.

Interchain Doubly-Bridged Α-Helical Peptides for the Development of Protein Binders

Inhibition of β-catenin/B cell lymphoma 9 protein−protein interaction using α-helix–mimicking sulfono-γ-AApeptide inhibitors

De Novo Computational Design for Development of a Peptide Ligand Oriented to VEGFR-3 with High Affinity and Long Circulation.

A Synthetic Bivalent Peptide Ligand of EphB4 with Potent Agonistic Activity

In Vivo Identification Of The Interaction Site Of Erbb2 Extracellular Domain With Its Autoinhibitor

Computational Design Of Antiangiogenic Peptibody By Fusing Human Igg1 Fc Fragment And Hrh Peptide: Structural Modeling, Energetic Analysis, And Dynamics Simulation Of Its Binding Potency To Vegf Receptor

De Novo Design of Isopeptide Bond-Tethered Triple-Stranded Coiled Coils with Exceptional Resistance to Unfolding and Proteolysis: Implication for Developing Antiviral Therapeutics

Designing Coiled Coils for Heterochiral Complexation to Enhance Binding and Enzymatic Stability

A Designed Cyclic Peptide Based on Trastuzumab Used to Construct Peptide-Drug Conjugates for Its HER2-targeting Ability.